1Q25 业绩基本符合我们预期 今年以来公司将推进多项调整政策以应对渠道变革及白热化价格竞争，线下公司将1）重塑基础营养品 价值链，通过低客单、低日服的方式与连锁药店合作打造多款单品以推动销量增长，1Q 推出的钙DK 产品表现好于预期，2Q 有望继续推出维生素、益生菌等产品；2）多模式专业化运作驱动重功能、刚需 品增长，如蛋白粉等；3）推出专业化、高净值的高端化产品如专供药线渠道的批文产品，提升复购。 线上渠道方面，公司有望透过高端产品升级，如双金标藻油、高纯极地鱼油等展开差异化，及基础营养 素的单品推广，同时公司将启动主品牌的抖音直播间搭建，提升品牌认知。我们预计以上措施有望自 2Q 起贡献额外收入增量，我们判断公司挑战最大的时期已经过去，未来收入及利润有望迎来逐季改 善。 盈利预测与估值 考虑线下渠道压力，下调25/26 年盈利预测6%/6%至8.3/9.8 亿元。公司当前交易在22.5/19.0 倍25/26 年 P/E；但考虑市场估值上行，维持目标价12.6 元，对应26.0/21.9 倍25/26 年P/E 和15.4%股价上行空间； 考虑保健品赛道长期空间广阔，维持跑赢行业评级。 风险 线上竞争加 ...

Core Viewpoint - Company reported a significant decline in Q1 2025 revenue and net profit, attributed to high base effects and weak demand, prompting a need for strategic adjustments in product and channel management [1][2][3] Financial Performance - Q1 2025 revenue reached 1.79 billion yuan, down 32.3% year-on-year; net profit attributable to shareholders was 450 million yuan, down 37.4%; and net profit excluding non-recurring items was 410 million yuan, down 42.4% [1] - The main brand "汤臣倍健" generated 983 million yuan in revenue, a decrease of 36.37% year-on-year; "健力多" revenue was 201 million yuan, down 46.15%; and Life-Space domestic products brought in 77 million yuan, down 36.19% [1] - International business, represented by LSG, achieved revenue of 244 million yuan, up 5.94% year-on-year, indicating relative stability [1] - Offline channel revenue was 988 million yuan, down 42.62%; online channel revenue was 766 million yuan, down 15.78%, with offline sales significantly impacted by reduced foot traffic and high base effects [1] Cost Management - Q1 2025 gross margin was 68.66%, a decrease of 1.24 percentage points, primarily due to a higher proportion of low-margin products and increased fixed costs from declining revenue [2] - Sales expense ratio was 30.29%, down 0.91 percentage points, reflecting effective cost control measures [2] - Management expense ratio increased to 5.77%, up 1.02 percentage points, due to the decline in revenue [2] - Overall, the net profit margin for Q1 2025 was 26.04%, down 1.13 percentage points year-on-year [2] Strategic Initiatives - In Q2, the company plans to launch new products aimed at revitalizing offline channel sales, including new formats for vitamins and probiotics, and targeting essential consumer groups [3] - The company will conduct offline product launch events to enhance brand visibility and consumer engagement [3] - Profit forecasts for 2025-2027 have been revised downwards due to ongoing weak demand, with projected net profits of 791 million yuan, 921 million yuan, and 1.024 billion yuan, representing reductions of 13%, 17%, and 19% respectively [3] - The company maintains a "buy" rating, emphasizing its leadership position in the dietary supplement industry and the sector's growth potential [3]